

BEIGENE CONTINUES GLOBAL GROWTH

70%

Increase YoY

Total Sales
\$595M

20+

assets in pipeline

	BRUKINSA®	Tiselizumab®
Total Sales	\$357.7M	\$144.4M
Increase YoY compared with the prior-year period	130%	12.6%

7

assets in Phase 3/registration

This graphic contains forward-looking statements. Please read the cautionary statement regarding forward-looking statements on page 9 of our earnings press release dated November 9, 2023.

Product sales may not add to total sales due to rounding.

[LEARN MORE](#)

“

Our BeiGene team delivered another strong quarter across our global product portfolio, driven by the ongoing successful launch of BRUKINSA®, where we continue to see rapid uptake across all approved indications, including CLL.

We are excited to have regained the rights to TEVIMBRA® worldwide, which is now approved in the EU and under regulatory review in 10 additional markets. We are now better positioned than ever before to execute on our global growth strategy while steadily improving operating leverage with moderate expense growth.

JOHN V. OYLER

Co-Founder, Chairman and CEO

”